ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Clinical trial NCT04431258 · COMPLETED

Trial details

NCT number: NCT04431258
Sponsor: Ability Pharmaceuticals SL
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2021-05-06
Primary completion: 2024-01-10
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.